China was at the epicentre of the COVID-19 pandemic in Q1 2020, and both government statistics and IQVIA Pharma Audits have confirmed the significant negative impact on the healthcare and life science industry. The outbreak of the pandemic exposed insufficient investment in the medical and healthcare market by the government, which resulted in shortage of medical service capabilities. Therefore, the Chinese government has made plans to accelerate investment in the healthcare industry.
IQVIA has identified three key sectors, which will benefit most from the “New Healthcare Infrastructure” investment scheme: county market, department level opportunities, focusing on intensive care units and IVD, and hospital digital solutions.
In this webinar, Paul Zhao, Head of IQVIA MedTech, China will evaluate investments in the three sectors and assess the business impact for MedTech companies as a result of the “New healthcare infrastructure” investments. We will also explore any opportunities and the challenges MedTech companies will face to meet the increasing demands.